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Summary Reproductive disorders are unusually common among women and men
with epilepsy. They are generally associated with and may be the consequence of
reproductive endocrine disorders. Both epilepsy itself and antiepileptic drug use have
been implicated in their pathophysiology. This review focuses on how temporolimbic
dysfunction in epilepsy may disrupt normal neuroendocrine regulation and promote
the development of reproductive endocrine disorders. The particular nature of the
dysregulation may relate to the laterality and focality of the epilepsy and some
hormonal changes may develop in close temporal relation to the occurrence of
epileptiform discharges. In women, reproductive endocrine disorders include poly-
cystic ovary syndrome, hypothalamic amenorrhea, functional hyperprolactinemia,
and premature menopause. In men, hypogonadism may be hypogonadotropic, hyper-
gonadotropic or related to hyperprolactinemia. The significance of these reproduc-
tive endocrine disorders is that theymay contribute not only to sexual dysfunction and
infertility but may also have an adverse impact on seizure control.
# 2007 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.Reproductive dysfunction is unusually common
among women and men who have epilepsy.1—3 It
generally manifests as menstrual disorder, hirsutism
and infertility in women,2 and loss of libido, impo-
tence and infertility in men.3 Reproductive dysfunc-
tion is often associated with and is the consequence
of reproductive endocrine disorders.1—3 Both epi-
lepsy and antiepileptic drugs (AEDs) have been cau-
sally implicated.1—3,4,5 Epilepsy and AEDS can target
a number of substrates to impact hormone levels.
These include the limbic system, hypothalamus,
pituitary, peripheral endocrine glands, liver, and* Tel.: +1 781 431 0277; fax: +1 781 431 0274.
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doi:10.1016/j.seizure.2007.11.025adipose tissue.6,7 Reproductive endocrine disorders
can lead not only to reproductive dysfunction but
also to exacerbation of epilepsy.6,7 An understand-
ing of these relationships and their underlying
neurological and neuroendocrine mechanisms is
important to the comprehensive management of
women and men with epilepsy.Reproductive dysfunction in women
with epilepsy
Hospital2,7,8 and community-based9 studies have
shown that menstrual disorders are more common
among women with epilepsy than in the general. Published by Elsevier Ltd. All rights reserved.
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as amenorrhea (no menses for 6 months), oligome-
norrhea (cycle intervals >32 days), polymenorrhea
(cycle intervals <26 days), abnormal variation in
cycle intervals (>4 days), and menometrorrhagia
(heavy menses and bleeding between menses.10
Cycle intervals between 26 and 32 days, rather than
the currently popular broader range of 21—35 days,
should be considered normal in womenwith epilepsy
because ovulatory rates drop substantially and sta-
tistically significantly, i.e. from >75% to <50%, out-
side of the 26—32 day range.10 Ovulation is
considered to be an important criterion in this
population because anovulatory cycles are asso-
ciated with greater seizure frequency.11,12 Men-
strual disorders, using the above definition, are
currently estimated to occur in one-third of women
with epilepsy as compared 12—14% of women in the
general population.6,10 More than one-third of
cycles in women with localization-related epilepsy
are anovulatory, as compared to 8—10% in con-
trols.10,13—15 There is conflicting evidence as to
whether anovulatory cycles are more common with
localization-related epilepsy or primary generalized
epilepsy.13—15 Women with idiopathic epilepsy are
only 37% as likely as unaffected female siblings to
become pregnant.16 This finding is not attributable
to marital rate or to seizure type, age at onset, or
family history of epilepsy.16 In comparison to the
general female population, fertility is reduced to
69—85% of the expected number of offspring among
married women with epilepsy, primarily TLE.17,18Reproductive endocrine disorders in
women with epilepsy
The most common reproductive endocrine disorder
in women with epilepsy as well as women in the
general population is polycystic ovary syndrome
(PCOS).2,19,20 PCOS occurs in 10—20% of women with
epilepsy compared with 5—6% of women in the
general population.6,7,18,20 This increased rate of
occurrence may be of considerable medical signifi-
cance because PCOS is associated with a higher
prevalence of migraine, emotional disorders, dia-
betes, cardiovascular disease, and female cancers
in the general population.20
PCOS is probably not a single nosologic entity, but
rather the common end point for a number of
pathophysiologic mechanisms, some of which may
be attributable to epilepsy itself2,7,19,20 or to the use
of AEDs, most notably valproate.5,14,15,21 PCOS
represents the failure of the ovarian follicle to
complete normal maturation during the menstrual
cycle or a series of cycles, a failure that is perhapsrelated to the presence of inadequate levels of
pituitary follicle-stimulating hormone (FSH), while
levels of luteinizing hormone (LH) are normal or
elevated.7,20 These conditions can produce two
results. There is a failure of ovulation and the
partially developed follicle is retained in the ovary
in the form of a tiny cyst.7,20 This partially devel-
oped follicle is secretory but deficient in aromatase,
the enzyme that converts testosterone to estrogen,
and, therefore has testosterone as its principal
secretory product. Testosterone may increase the
positive feedback of estrogen on pituitary LH secre-
tion,21 resulting in increased ovarian steroid secre-
tion, which, under these circumstances, may be
predominantly testosterone and can result in hyper-
androgenism. The testosterone is aromatized in
peripheral adipose tissue, generally producing
high—normal levels of estrogens which is a major
source of the estrogen feedback on the pituitary.
The persistent occurrence of such cycles results in
hyperandrogenic chronic anovulation, which is cur-
rently the simplest and perhaps the most utilitarian
definition of PCOS.20,22
Hypothalamic amenorrhea (HA — amenorrhea
associated with low gonadotropin and estrogen
levels and diminished LH response to gonadotropin
releasing hormone (GnRH) challenge), functional
hyperprolactinemia (elevated prolactin levels with-
out identifiable pituitary lesion) and premature
menopause (cessation of ovarian function featuring
amenorrhea and elevated gonadotropin levels) have
also been found to be overrepresented in women
with epilepsy.2,7,18,23,24 In an investigation of 50
consecutive women with clinical and electroence-
phalographic features of TLE, 28 (56%) had amenor-
rhea, oligomenorrhea, or abnormally long or short
menstrual cycle intervals.2 Nineteen of the 28
women with epilepsy and menstrual disorders
(68%, 38% overall) had readily identifiable reproduc-
tive endocrine disorders: PCOS in 10, hypothalamic
amenorrhea in 6 (12%), premature menopause, in
this study before 30 years of age, in 2 (4%), and
functional hyperprolactinemia in 1 (2%). The num-
bers of women with clinical and endocrine features
of PCOS (20%) and of HH (12%) were significantly
greater than the estimated frequencies (5% for PCOS
and 1.5% for HH) in the general female population.
The data showed no significant relationship over-
all between the occurrence of menstrual disorders
and the use of AEDs (53% among users versus 60%
among nonusers) and raised the possibility that
epilepsy itself may be a factor.2 PCOS was more
common among the untreated (30%) than the trea-
ted (13%) women with epilepsy. Treatment AEDs
were of the enzyme-inducing variety. The lesser
occurrence of PCOS among women treated with
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also been demonstrated in an independent investiga-
tion by Hamed et al.8 This is in contradistinction to
the notable relationship that has been demonstrated
between the enzyme-inhibiting AED, vaproate.5
A potential role for the epileptic substrate has
been suggested by the finding that among women
with unilateral epileptic foci, PCOS is associated
with left temporal and right nontemporolimbic foci
whereas HA has been found to bemore commonwith
right TLE25,26 and by the finding that untreated
women with primary generalized epilepsy have
higher pulse frequency gonadotropin releasing hor-
mone secretion than normal controls.27 Increased
pulse frequency or amplitude of gonadotropin
releasing hormone secretion by the hypothalamus
results in preferential LH versus FSH secretion by the
pituitary,28,29 which would promote the develop-
ment of PCOS.Pathophysiology of reproductive
endocrine disorders in women with
epilepsy
The brain controls reproductive function primarily
through hypothalamic regulation of pituitary secre-
tion.29 Regions of the hypothalamus that are
involved in the regulation, production, and secre-
tion of gonadotropin-releasing hormone (GnRH)
receive extensive direct connections from the cer-
ebral hemispheres, especially from temporolimbic
structures that are commonly involved in epilepsy,
and most notably from the amygdale.1,2 Significant
relationships have been uncovered through which
epilepsy may influence the function of this complex
neuroendocrine system.
Animal experimental studies have shown that the
amygdala can be parceled into cytoarchitectoni-
cally distinct functional divisions that exert oppos-
ing modulatory influences on pituitary hormone
secretion30,31 reproductive function30,31 and the
resting membrane potentials of individual ventro-
medial hypothalamic neurons.32 Following amygda-
loid seizures, fos, a protein marker for neuronal
activation, is increased in the sexually dimorphic
regions of the hypothalamus that are involved in
reproductive endocrine secretion and reproductive
function, i.e. the medial preoptic, ventromedial,
and ventral premammillary nuclei, but much less so
in other hypothalamic nuclei.33 Seizures also
decrease GnRH fiber staining in the ventromedial
hypothalamus.34,35 Both of these responses to uni-
laterally provoked amygdaloid seizures occur in a
laterally asymmetric fashion with significantly and
substantially greater involvement ipsilaterally thancontralaterally to the seizure focus.33,35 Preferen-
tial ipsilateral involvement is potentially important
because there are lateralized biochemical and phy-
siologic differences between the left and right sides
of the limbic system and also of the hypothalamus.
Specifically, anovulatory cycles are more common
with right than with left unilateral amygdalec-
tomies.36 GnRH content in the ventromedial
hypothalamus of the female rat has been reported
to be 50—100% greater in the right ventromedial
hypothalamus than in the left ventromedial
hypothalamus.37,38 The left and right vagus nerves
exert different modulatory influences on ovarian
structure and function.37,38 The experimental find-
ings in the female rat are consistent with the notion
that disruption of the normal temporolimbic mod-
ulation of hypothalamopituitary function may inter-
fere with ovarian hormonal secretion and promote
the development of reproductive endocrine disor-
ders.39 The findings suggest, moreover, that the
reproductive neuroendocrine system, like many
other brain systems, shows a lateralized asymmetry
that might, by virtue of ipsilaterally predominating
effects, contribute to the development of distinct
reproductive endocrine disorders in association with
unilateral left and right sided epileptic foci.40
There are also important clinical findings which
indicate that reproductive endocrine function dif-
fers between women with epilepsy and normal con-
trols and that the laterality and focality of epilepsy
may be important determinants of reproductive
endocrine function.7 Unilateral temporolimbic dis-
charges are associated with laterally differing, con-
sistent, predictable, stochastic directional changes
in hormonal secretion at all levels of the reproduc-
tive neuroendocrine axis, i.e. hypothalamus, pitui-
tary and ovary (Fig. 1).7 These directional changes
are consistent with the finding that different repro-
ductive disorders may develop in relation to left-
and right-sided temporolimbic epilepsy. Specifi-
cally, LTLE is associated with significantly higher
pulse frequencies of GnRH secretion.7 Higher GnRH
pulse frequency, in turn, is associated with higher
LH/FSH ratios and higher serum testosterone levels.
This combination of neuroendocrine changes char-
acterizes PCOS and is consistent with the previously
suggested association between left unilateral tem-
porolimbic epilepsy (TLE) and PCOS. Ten percent to
20% of women with TLE have been found to have
PCOS, in comparison with about 5—6% in the general
population.20 Right unilateral TLE is associated with
lower GnRH pulse frequency which is associated
with decreased LH and estradiol levels.2,7 These
features are characteristic of HA.2,7,18,25,26 Some
hormonal changes can show close temporal relation-
ship to the occurrence of interictal epileptiform
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Figure 1 Reproductive endocrine function in women with epilepsy and controls. Reproductive endocrine data in
medicated and unmedicated women with left and right TLE. Hypothalamic parameters: LHPF was significantly more
variable among women with TLE than among controls (6.0  0.7 vs. 5.8  1.7; p < .01). Women with LTLE had higher
LHPF than women with RTLE (6.5  1.5 vs. 4.9  1.7; p < .01), regardless of medication use (untreated: 7.2  1.6 vs.
4.0  0.8; p < .01). LHPA was significantly higher among untreated women with TLE than among treated women
(3.0  1.4 vs. 2.3  0.7; p = .05) and controls (2.1  0.6; p < .05) without any significant laterality effect. PRLPF
showed no significant findings in relation to epilepsy, epilepsy laterality or medication use. PRLPA was significantly more
variable among women with TLE than among controls (4.6  6.1 vs. 3.0  1.5; p < .001). Variability was significantly
greater among women with RTLE than among women with LTLE (6.7  8.6 vs. 3.0  1.8; p < .001). PRLPA values were
significantly greater for treated women with RTLE (8.1  9.6) than for untreated women with RTLE (2.4  0.7; p < .05),
as well as women with LTLE (treated: 2.9  1.7; p < .05; untreated: 3.5  2.3; p < .10) and controls (3.0  1.5; p < .05).
LH/FSH was significantly greater for women with LTLE than for women with RTLE (1.1 p  0.5 vs. 0.65  0.35; p < .01),
regardless of medication use (untreated: 1.4  0.6 vs. 0.58  0.10; p < .01). Pituitary parameters: LH was more variable
among women with TLE than among controls (4.9  2.5 vs. 4.7  1.5; p = .05). The mean value was higher among
untreated women with LTLE (7.1  3.7) than among treated women with LTLE (5.0  1.9; p < .10) and controls
(4.7  1.5; p < .10), and more than two-fold greater than the mean value for untreated women with RTLE
(3.1  0.9; p = NS). FSH was more variable among women with TLE than among controls (5.9  2.0 vs. 5.2  0.9;
p = .01). FSH was significantly higher for women with RTLE (6.7  2.0) than women with LTLE (5.3  1.8; p < .05). This
lateralized difference among women with TLE was statistically significant only among treated women (7.1  2.0 vs.
5.4  2.0; p < .05). PRL did not show any significant finding in relation to epilepsy, epilepsy laterality or medication use.
Peripheral gland parameters: Testosterone levels were significantly greater for LTLE than RTLE (35  16 vs. 22  9;
p < .01) as they were for controls (32  11 vs. 22  9; p < .01). There was no significant finding in relation to medication
use. Estradiol levels were significantly greater among controls than women with epilepsy (35  6 vs. 22  8; p < .001)
regardless of medication use (untreated: 25  7; p < .01; treated: 21  7; p < .01). E2 levels were significantly greater
for LTLE than RTLE (25  7 vs. 18  6; p < .01) and each was significantly less than controls (35  6; p < .01). Lower E2
values with medication use were attributable to the use of enzyme-inducing drugs (E2 for barbiturate, carbamazepine,
phenytoin users vs. controls = 14.5  4.5 vs. 35.4  6.2; p < .001) as opposed to non enzyme-inducing drugs (E2 for
gabapentin, lamotrigine, valproate users vs. controls = 28.3  9.4 vs. 35.4  6.2; p = N.S.). Untreated women with TLE
had substantially lower E2 levels (24.9  7.6) than controls (35.4  6.2), albeit without statistical significance ( p < .20).
DHEAS values were significantly greater for controls than for women with TLE (189.2  51.1 vs. 110.4  72.7; p < .001).
DHEAS values were significantly greater for controls (189.2  51.1; p < .01) and untreated women with TLE
(160.1  65.3; p < .01) than for treated women with TLE (93.8  68.2). Lower DHEAS values with medication use were
attributable to the use of enzyme-inducing drugs (DHEAS for barbiturate, carbamazepine, phenytoin users vs. controls:
49.2  37.2 vs. 189.2  51.1; t-test p < .001) as opposed to non enzyme-inducing drugs (DHEAS for gabapentin,
lamotrigine, valproate users = 108.5  50.7 vs. 189.2  51.1; t-test p = N.S.). Values for enzyme-inducing drug users
were significantly lower than for non enzyme-inducing drug users (49.2  37.2 vs. 108.5  50.7; p < .001).
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Figure 2 Interictal paroxysmal EEG discharges and closely related reproductive endocrine changes in gonadotropin and
prolactin secretion in women with left and right sided unilateral temporolimbic epilepsy. Left temporal discharges were
often accompanied by abnormal suppression (>104.3 min without a pules peak) of LH pulsatility and subsequent
abnormal >27% elevation in mean baseline LH levels. Right temporal discharges were often followed by abnormally
high prolactin pulse peak values and continuation of LH pulsatility.
106 A.G. Herzogdischarges and these vary in relation to the later-
ality of the discharges (Fig. 2).7 Specifically, the
occurrence of abnormal prolactin pulse amplitudes
predominantly after right temporolimbic dis-
charges, and the suppression of LH pulsatility with
subsequent elevation of LH baseline values after left
temporolimbic discharges, raise the possibility that
paroxysmal interictal discharges may acutely dis-
rupt normal hypothalamopituitary endocrine func-
tion. Menstrual disorders have been found to be
significantly more common among women with
interictal discharges as well with associated abnor-
mal neuroendocrine regulation.7
AEDs have substantial and differential effects on
reproductive hormone levels.7 There are notable
differences between enzyme-inducing and non-
inducing drugs with the former being associated
with lower serum levels of some ovarian and adrenal
steroids: estradiol, testosterone and dehydroepian-
drosterone sulfate.7 There is also considerable evi-
dence to suggest that menstrual disorders,
anovulatory cycles, polycystic ovaries and PCOS
are more common among women who take valpro-
ate and, particularly so, when started early during
the reproductive years.15,41 These findings impli-
cate valproate in the pathophysiology of PCOS.
An alternative and possibly unifying considera-
tion is that PCOS may develop as an interactional
effect between AED use and epilepsy.20,42 Specifi-
cally, there is the possibility that epilepsy may
promote PCOS development and that enzyme-indu-
cing AEDs treat not only the epilepsy but also the
PCOS by enzyme induction that increases the synth-
esis of sex hormone binding globulin and the meta-
bolism of testosterone resulting in lower levels of
bioavailable testosterone.20,42 In contrast, enzyme-
inhibiting drugs, most notably valproate, may retard
the aromatization of testosterone to estrogen and
potentiate the development of epilepsy-related
hyperandrogenism and hence PCOS.20,42 Antiseizure
medications other than valproate, therefore, may
treat hyperandrogenism and thus PCOS, whereas
valproate therapy may not. This mechanism,
thereby, could contribute to a higher occurrence
of PCOS in valproate-treated women with epilepsy.
If this were an extant mechanism, then valproate
would not be the primary cause of PCOS, yet its
selection as treatment may be an important factor.Reproductive dysfunction in men with
epilepsy
Diminished libido or potency occurs in approxi-
mately 20% of men with epilepsy as determined
by standardized questionnaire survey.4,43 Olderstudies, using mostly structured or unstructured
interviews, found higher frequencies ranging from
38 to 71%.3,6,43—49 Abnormal semen analysis, includ-
ing decreased sperm count, abnormal morphology
or impaired motility, have been reported in upwards
of 90% of men with epilepsy.41,44,46 Men with idio-
pathic epilepsy are only 36% as likely as male unaf-
fected siblings to ever father a pregnancy.16 This
reduction is associated with localization-related
epilepsy, onset of seizures before 20 years of age,
and absence of a family history of epilepsy.16 The
effect is mitigated by reduced marital rates. Among
married men with epilepsy, reproductive disadvan-
tage was confined to those with onset before 10
years of age.16Reproductive endocrine dysfunction in
men with epilepsy
Hypogonadism refers to diminished gonadal func-
tion as determined by low serum testosterone level
and/or decreased or abnormal sperm production.6 It
can manifest as diminished sexual interest, potency,
fertility, energy, mood, competitive drive, bone and
muscle mass, and secondary sexual characteristics.
Physical signs include a loss of male escutcheon,
gynecomastia and testicular atrophy. The clinical
impression of hypogonadism can be verified by
laboratory testing. It may be hypogonadotropic,
hypergonadotropic or associated with functional
hyperprolactinemia.3 Testosterone exists in three
major forms: (1) tightly bound to sex hormone
binding globulin (SHBG, 45—50%), (2) loosely bound
to albumin (50—55%), and (3) unbound (1—2%).6 The
albumin-bound and free portions are available to
tissues and, therefore, constitute the clinically
important bioavailable portion. Measures of bioa-
vailable testosterone (BAT) suggest that hypogonad-
ism may occur in one-third of men with
temporolimbic epilepsy4,43 BATshows a substantially
earlier and greater age-related decline in men with
epilepsy than in controls.4,43 In a sample of men with
localization-related epilepsy, we found that BAT fell
below normal control levels in 11% of men between
20 and 30 years, 27% between 30 and 40 years and
89% between 40 and 50 years of age.43 Several4,46—49
but not all,50 investigations have found significant
relationships between reduced serum BAT measures
and sexual dysfunction. Men with epilepsy may show
evidence of sexual dysfunction in the setting of low-
normal BAT levels at which men in the general
population may not show clinical manifesta-
tions.3,4,6,43 This may constitute an argument
against the importance of the BAT level. Alterna-
tively, higher BAT levels may be required for normal
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substrate of temporolimbic epilepsy.Pathophysiology of reproductive
endocrine disorders in men with
epilepsy
The etiology of hypogonadism as well as reproduc-
tive and sexual dysfunction in men with epilepsy has
been attributed to a number of possible causes.
These include: (1) psychosocial stress; (2) AEDs;
and (3) epilepsy itself.6
Psychosocial stress associated with epilepsy may
play an important role in hypogonadism.51—56 From a
neuroendocrine perspective, stress response
involves the activation of the hypothalamo—pitui-
tary—adrenal (HPA) axis.6,52—56 Cortisol levels are
higher in individuals with epilepsy than in controls,
not unlike individuals with depression.53 Unlike
depression, however, diurnal variation is often lost
in epilepsy.53 Factors that increase the activity of
the HPA axis interfere with reproductive endocrine
secretion as well as reproductive function6,52—56 and
may contribute to seizure exacerbation.6 Stress
increases the release of proopiomelanocortin
(POMC) the precursor protein that is cleaved to form
ACTH and endorphin,54,56 both of which inhibit
gonadotropin secretion and reproductive func-
tion.52,56 ACTH increases cortisol secretion; endor-
phins increase dehydroepiandrosterone production.
Both of these steroids have GABA-negative allostea-
ric modulatory properties that can lower seizure
thresholds and increase anxiety.6,57
Enzyme-inducing AEDs can directly suppress
gonadal testosterone synthesis, increase testoster-
one binding by the induction of sex hormone binding
globulin (SHBG) synthesis, and increase serum estra-
diol levels in absolute or relative terms.4,43,58
Although constituting only 1% of the total reproduc-
tive steroid, estradiol exerts one-half of the nega-
tive feedback on the hypothalamopituitary axis.6
Therefore, a small increase in estradiol level, pre-
sumably as a result of AED induced increase in
aromatase activity, could have a disproportionately
large negative feedback effect on gonadotropin
production, thereby contributing to hypogonadism.
In a comparison of sexual/reproductive function and
reproductive hormone levels among 85 men with
epilepsy who took various AEDs [25 on carbamaze-
pine (CBZ), 25 on phenytoin (PHT), 25 on lamotri-
gine (LTG) and 10 untreated for at least 6 months
(No AED)] and 25 controls, Herzog et al.4,43 found
that sexual function scores (S-scores), hormone
levels (bioactive testosterone, estradiol), hormone
ratios (bioactive testosterone/bioactive estradiol)and gonadal efficiency (bioactive testosterone/
luteinizing hormone) were significantly greater in
the control and LTG treated groups than in the CBZ
and PHT treated groups. Sex hormone binding glo-
bulin was significantly higher in the CBZ and PHT
groups than in all other groups. Among the signifi-
cant findings were the following. S-scores were
below the control range in 20% of the men with
epilepsy, including 32% on CBZ, 24% on PHT, 20% on
no AEDs and 4% on LTG. Bioactive testosterone was
below the control range in 28.2%, including 48% on
CBZ, 28% on PHT, 20% on no AEDs and 12% on LTG.
Among men with epilepsy who had low S-scores,
70.6% had bioactive testosterone levels below the
control range as compared to 17.6% amongmen with
normal S-scores. Among men with epilepsy who had
abnormally low bioactive testosterone, 50.0% had
low S-scores; among men with normal bioactive
testosterone, 8.2% had low S-scores. Bioactive tes-
tosterone decline with age was greater among men
with epilepsy than among controls and notably
greater in the CBZ and PHT groups than in the
LTG and untreated groups. Overall, sexual function,
bioavailable testosterone levels and gonadal effi-
ciency in men with epilepsy who took lamotrigine
were comparable to control and untreated values
and significantly greater than with carbamazepine
or phenytoin treatment.
The temporolimbic system is one of the most
common sites of origin or involvement in adult
epilepsy. It also has integral roles in reproductive
endocrine regulation and feedback as well as in
sexual and reproductive function.1,3,6 Conse-
quently, the development of epileptiform dis-
charges in medial temporal lobe structures may
disrupt hypothalamic regulation of pituitary secre-
tion and hence alter gonadal function and repro-
ductive function (Fig. 3).1,3,6 Experimental animal
investigations have shown that focal limbic seizures,
as well as generalized seizures, disrupt normal gona-
dal structure, physiology and serum androgen levels
in the male rat,59 and that the induction of seizures
in the amygdala, but not in the motor cortex,
produces hyposexuality in the male cat.60 Clinical
studies suggest that temporolimbic epilepsy may be
associated with altered gonadotropin response to
GnRH infusion regardless of AED use.61 Mean base-
line LH and LH pulse frequency are significantly
more variable among men with epilepsy than among
controls and may show bidirectional changes that
relate to EEG laterality.62 Epileptiform discharges in
men are accompanied by acute elevations in pro-
lactin levels63 and may also be accompanied by
acute changes in patterns of LH secretion.6 Quigg
et al.64 have found that interictally, LH pulse fre-
quency and mean concentration are lower and pulse
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Figure 3 Gonadal steroid secretion is regulated by
pituitary gonadotropins, luteinizing hormone (LH) and
follicle-stimulating hormone (FSH), that are, in turn,
regulated by the pulsatile secretion of gonadotropin
releasing hormone (GnRH) by sexually dimorphic repro-
ductive endocrine nuclei in the hypothalamus. The amyg-
dala can be parceled into two cytoarchitectonically
distinct functional divisions, corticomedial and basolat-
eral, that exert opposing modulatory influences on the
hypothalamic regulation of pituitary secretion. The amyg-
dala also regulates the autonomic (sympathetic — Symp
N.S. and parasympathetic — Vagus) innervation of the
testes, that likely play a trophic as well as endocrine
regulatory function, and receives vagal afferents (dotted
line)that impact amygdaloid excitability. Antiepileptic
drugs differentially affect gonadal testosterone biosynth-
esis, hepatic sex hormone binding globulin (SHBG) produc-
tion, and aromatization and reduction of testosterone to
potent glutamatergic neuroexcitatory (estradiol — E2)
and GABAergic neuroinhibitory (androstanediol — ADiol)
metabolites that may feed back (dashed line) to modulate
temporolimbic neuroexcitability and seizures.amplitudes are higher than in controls. Postictally,
they found no change in mean pulse frequency but
did detect a significant change in the regularity of
pulse occurrence. Clinically, there may be a greater
occurrence of sexual dysfunction in men with right,
rather than left, lateralized temporolimbic epi-
lepsy.3,65,66 There is also animal experimental evi-
dence to suggest that the left and right sides of the
hypothalamus may exert different effects on sexual
function.67 Testosterone levels may be lower in men
with temporal foci as compared to extratemporal
foci.68 Successful temporal lobectomy in hypogona-
dal men with intractable seizures has been asso-
ciated with normalization of testosterone levels69
and improvement in sexual interest and function.70
A remarkably high frequency of abnormal findings in
semen analysis has been reported to occur among
untreated as well as treated men with epilepsy.44,71
Changes in reproductive steroid concentrations
may impact seizure tendencies as well as reproduc-
tive function. While estrogen is proconvulsant andprogesterone is anticonvulsant in most adult animal
models of LRE, the effect of testosterone on experi-
mental seizures appears to be mixed. This may be
related to its ready metabolism by aromatase to
estradiol which has neuroexcitatory effects,72 while
it can also be metabolized by reductase to dihydro-
testosterone and further to androstanediol, a
potent GABAergic steroid with antiseizure proper-
ties.6,73 While testosterone replacement has proven
only moderately effective in restoring sexual func-
tion, possibly because of its ready metabolism to
estrogen, especially in the setting of AEDs, one pilot
study has reported superior results using combined
treatment with testosterone and an aromatase inhi-
bitor that blocked the transformation of testoster-
one to estradiol.74 Combined therapy was
associated with seizure reduction as well.74 The
neuromodulatory role of reproductive steroids sug-
gests that a greater understanding of neuroendo-
crine regulation in men with epilepsy may be
important not only for reproductive function but
also for optimal management of seizure disorders.References
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